Intermediate and long acting insulin switches

By rray, 10 August, 2023
Exclude Patient Type Detail Header
Yes
Footnote
<sup>1</sup> Levemir. Prescribing information. Novo Nordisk Inc.; 2022.<br><br>
<sup>2</sup> Lantus. Prescribing information. sanofi-aventis U.S. LLC; 2022.<br><br>
<sup>3</sup> Toujeo. Prescribing information. sanofi-aventis U.S. LLC; 2022.<br><br>
<sup>4</sup> Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: A narrative review for primary care. <i>Ann Med</i>. 2021;53(1):998-1009. <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231382><u>Free, full-text article</u></a>. Accessed July 28, 2023.<br><br>
<sup>5</sup> Basaglar. Prescribing information. Eli Lilly and Company; 2021.<br><br>
<sup>6</sup> Tresiba. Prescribing information. Novo Nordisk Inc.; 2022.<br><br>
<sup>7</sup> Eli Lilly and Company. Humulin R U-500 human insulin monotherapy delivers a dual action, providing the properties of both basal and mealtime coverage when dosed as directed. Humulin R U-500 website. Accessed July 28, 2023. <a href=https://www.humulin.com/hcp/dosing-titration#insulin-activity><u>https://www.humulin.com/hcp/dosing-titration#insulin-activity</u></a>.
Detail Type
Image
Patient Type Detail Header (Long)
Intermediate- and long-acting insulin switches